華東醫藥(000963.SZ):糖尿病管線的重要品種今年有望繼續保持較快增長
格隆匯2月20日丨華東醫藥(000963.SZ)於2023年2月15日14:30-16:00;2月16日11:00-11:40、14:00-15:00接受機構現場調研時表示,公司百令系列及阿卡波糖系列產品預計今年會處於穩定增長狀態,較前兩年有所改善。公司糖尿病管線的重要品種今年也有望繼續保持較快增長,利拉魯肽注射液兩個適應症均有望在今年獲批上市帶來新的增量。免疫抑制劑產品保持穩步增長,心血管領域核心產品保持快速增長,注射用醋酸卡泊芬淨、注射用米卡芬淨鈉,以及新獲批上市的甲苯磺酸索拉非尼片、卡格列淨片等預計也將對公司今年的經營業績帶來積極影響。此外,公司負責進行市場推廣的尼欣那®(苯甲酸阿格列汀片)、淫羊藿素軟膠囊等也有望貢獻一定銷售業績。公司與科濟藥業合作在中國進行商業化的澤沃基奧侖賽注射液於2022年10月遞交了上市許可申請,目前處於審評階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.